Swiss Life Sciences has partnered with Bio Zu Farm for the management of its indoor facility, as well as research and development of cannabis genetics for specific applications in healthcare.
Swiss Life Sciences Group has announced a new partnership with cannabis and CBD genetics experts, Bio Zu Farm, which will now be managing the setup and operation of Swiss Life Sciences’ state-of-the-art production facility in Switzerland. The partnership will also see ongoing research and development in genetics for specific purposes and applications in healthcare.
Swiss Life Science’s objective is to make available globally a selection of proprietary medical cannabis strains and associated medical treatments, with irrefutable tracking and integrity, from genetics to end product.
Striving for technical excellence
Swiss Life Sciences and its Swiss subsidiary, Savim SA, are developing specific proprietary strains of cannabis with a particular focus on future medical treatments for a variety of illnesses and diseases such as epilepsy, autism, and the different stages of COVID-19.
The company says it aims to develop genetics that perfectly match the terpene profiles, THC levels and CBD levels that are already being successfully used in treatments, and improve on them with elite genetics.
Bio Zu Farm, which is now the owner of leading cannabis strains such as BZ1, one of Europe’s most popular strains, will be managing the setup and operation of Swiss Life Sciences’ production facility which uses advanced propagation systems and blockchain management technology to deliver pharmaceutical-grade cannabis strains to the CBD healthcare and medical industries.
JP Engele, COO of Savim, commented: “We have spent over two years carrying out much granular research, both vertically and horizontally, in choosing the partnerships that we want to have here in Switzerland. There are many seed producers, but none of them come with the pedigree of genetics expertise and integrity of Bio Zu Farm.
“Both Matteo and President and Founder Davis Ramelli, are consummate professionals and genuinely care about moving this industry from a ‘grey area’ to being clearly in the white and transparent field of play. This allows everyone to feel comfortable and enjoy products that will be life-changing for so many. We will continue to form partnerships here in Switzerland, and are very happy with the integration we are achieving and the team we are building. Hands-down, Bio Zu are the right partners.”
Matteo Ambrosini, COO of Bio Zu Farm, added: “We are very excited to be working with Swiss Life Sciences Group and the team at Savim SA to bring our experience and expertise in the field of cannabis-related genetics to the wider consumer marketplace. This fits with our own strong values and commercial objectives.
“The group’s objective to build from the ground up, by developing their own strains of cannabis genetics, is refreshing in the cannabis industry. Looking at what is already out there and making it better and more widely available has always been something we admire. The attention to detail we are taking in the set-up and operation of the production facility is guided by SLSG, to make sure that we will be at the cutting edge of the industry. Striving for technical excellence and innovation at every stage is our goal.”
[activecampaign form=31]
